SUMMARY Homovanilic acid (HVA) was determined in the lumbar CSF of 12 patients with Huntington's disease and 12 with Sydenham's chorea before and after probenecid administration. The means of HVA concentration (basal and after probenecid) were lower in those with Huntington's disease than in controls, and were even lower in a sub-group characterised by increased tone and slowness of voluntary movement. There was no correlation between CSF HVA values and the severity of abnormal movements, nor with length of the illness and age of the patients with Huntington's disease. The mean basal HVA concentration did not differ from controls in those with Sydenham's chorea but the accumulation with probenecid was significantly lower. These results suggest a decrease in cerebral dopamine release in both forms of chorea.
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About one third of the homovanilic acid (HVA) derived from the catabolism of dopamine (DA) and released in the striatum enters the CSF in the lateral ventricle.' 2 There is some evidence to suggest that the concentration of this acid metabolite in ventricular CSF, is related to the concentration in the striatum.24 But the concentration of HVA cisternal and lumbar CSF is lower, and the correlation with striatal levels disappears.' 5 6 At least three mechanisms are responsible for the lower HVA levels-lumbar CSF (1) the diffusion of the HVA "jet," (2) the CSF circulation, (3) Curzon'6 in two patients with severe akinetic-rigid Huntington's disease. The increment of CSF HVA after probenecid was reported as normal in two patients,26 but decreased in two other papers reporting groups of eight and two patients respectively with Huntington's disease. '8 27 There is little information available on the concentrations of CSF HVA in Sydenham's chorea, but again values within the range of normal have been reported.'6 29 We have studied two groups of patients, 12 with Sydenham's chorea and 12 with Huntington's disease. CSF HVA was determined before and after probenecid administration. Correlations with clinical data were made.
Material and methods
The main features of the Huntington's disease and Sydenham's chorea patients are summarised in tables 1 and 2. Severity of abnormal movements was assessed by the AIM scale (maximum 42) and the criteria for gradation of rigidity and bradykinesia were those defined by Duvoisin.30 None of the patients was taking any drug for at least three weeks before determination of CSF HVA. The nature of the investigation was explained to the patient or to a responsible relative and consent was obtained. Three days before the lumbar puncture the patient was kept on a diet that excluded all the foods known to influence monoaminergic metabolism. 258 6+38 9 ng/ml: post-probenecid HVA value 136-2+35 ng/ml (mean+11 SD).
Results
The data are summarised in tables 1 and 2. The mean CSF HVA in the patients with Huntington's 
